Project Grant R41TR005388
Award Date 8/7/25
Completion Date 7/31/26
Dollars Obligated $313K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- This federal Project Grant award of $175,500 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the role of alternative splicing in Facioscapulohumeral Muscular Dystrophy (FSHD). The research project, performed by The Washington University, has three key objectives: 1) Characterize the interactions between the transcription factor DUX4 and RNA in...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $124,308 to the Fred Hutchinson Cancer Center in Seattle, WA to investigate the role of human satellite II (HSATII) RNA in the pathogenesis of facioscapulohumeral muscular dystrophy (FSHD). The research aims to determine the composition of HSATII-derived ribonucleoprotein...
- This $499,300 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research by Myogene Bio LLC, a woman-owned small business in San Diego, California, to advance manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophy (DMD). The key products and services to be delivered include: 1) Optimizing the upstream...
- This federal Project Grant award of $350,000.00 from the National Center for Advancing Translational Sciences (NCATS) under the CFDA 93.350 program is supporting the development of a fibroblast-derived engineered extracellular vesicle (FIEEV) platform for the targeted delivery of RNA therapeutics to treat Charcot-Marie-Tooth disease type 1A (CMT1A). The project aims to refine the FIEEV technology as a novel non-viral delivery method to overcome the limitations of current RNA therapeutic...
- This $313,148 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support the development of an in vivo imaging platform for myotonic dystrophy type 1 (DM1) drug discovery. The project aims to create novel fluorogenic RNA aptamer-based reporters that can detect drug-induced changes in toxic RNA foci formation and sequestration of the MBNL splicing...
- This federal Project Grant award of $671,240 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to develop enhanced dystrophin gene therapies for Duchenne muscular dystrophy (DMD). The University of Washington will conduct this research from January 2025 through December 2029. The project aims to design and test micro-, mini-, and full-length dystrophin gene...
- This $420,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Myogene Bio LLC, a woman-owned small biotechnology company, to evaluate the efficacy of CRISPR gene editing technology in treating Duchenne muscular dystrophy (DMD). The research aims to correlate CRISPR efficacy with functional outcomes in preclinical DMD models, building on the company's previous federal grant awards focused...
- The federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,507,500 to the University of Massachusetts Medical School (UMass Medical) to expand the capabilities of third-generation DNA/RNA sequencing technologies. The project aims to generate rapid and cost-effective training libraries to allow for direct detection of common DNA damage and RNA modifications, enabling innovative...
- This $445,000 Project Grant award, funded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports a research project focused on leveraging long-read transcriptomics to elucidate transcriptome complexity and advance genomic medicine. The central objective is to harness the power of long-read RNA sequencing to provide unprecedented insights into alternative splicing and its impact on gene products, which is...
- The federal Project Grant award of $420,984.00 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to develop statistical methods for analyzing deep mutational scanning (DMS) data. The research aims to improve the interpretation of DMS experiments, which can measure how genetic variants affect protein function, in order to better understand the mechanisms underlying basic biology and...